MabVax Therapeutics Holdings, Inc., (OTCPINK:MBVX) is organized around development of proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The firm's lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company also has a range of other product candidates. With various research agreements and collaborations with Memorial Sloan Kettering Cancer Center. the firm also has a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon.
